NanoPhoria Bioscience has announced the second closing of its series A financing round, including a €15 million equity investment from the European Innovation Council (EIC) Fund. The company recently received the largest ever Series A financing round in Italian biotech history, Alongside the EIC, NanoPhoria also received… Read More
Gene therapy company AskBio has announced encouraging results from the Phase I trial of gene therapy AB-1002 in participants with congestive heart failure. The 12-month data set, revealed in Nature Medicine, confirms that meaningful improvements were recorded across several efficacy assessments and no adverse events… Read More
Corteria Pharmaceuticals has initiated a Phase II trial in heart failure and Phase I trial in obesity with its first-in-class corticotropin‑releasing factor receptor 2 (CRF2) agonists, COR‑1167 and COR‑1389. CRAFT-WHF Phase II trial of COR-1167 in worsening heart failure COR-1167… Read More
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has authorised the use of Beyonttra (acoramidis) in the UK for the treatment of wild-type or variant transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM). ATTR-CM is a progressive, fatal disease that presents as an infiltrative, restrictive cardiomyopathy… Read More
AskBio announced that the first participant has been randomised in Europe in GenePHIT (Gene PHosphatase Inhibition Therapy), a Phase II clinical trial of AB-1002 for the treatment of congestive heart failure (CHF). GenePHIT is an adaptive, double-blind, placebo-controlled, randomised, multicentre trial to evaluate the… Read More
At this year’s annual European Society of Cardiology conference (ESC Congress 2024), which took place from 30 August – 2 September, AstraZeneca presented research that spans 38 abstracts, focusing on unmet need in heart failure (HF) and transthyretin-mediated amyloid cardiomyopathy (ATTR-CM), and other chronic diseases. Data highlights… Read More
A new study indicates that anti-obesity drug semaglutide helps prevent cardiac events among overweight people who have cardiovascular disease, even if they also have heart failure. The results follow a previous finding that weekly injections of semaglutide were linked to a 20% reduction in major adverse cardiac events (MACE) such… Read More
Heart failure is a collection of different diseases, which can be hard to define and treat through routine clinical practice. Heart failure affects 64 million people globally and approximately half of patients with heart failure die within five years of diagnosis. Real-world data presented at the European Society of Cardiology’s… Read More
AstraZeneca has added a novel target for heart failure to its discovery portfolio through its collaboration with BenevolentAI. This novel target for heart failure was discovered using BenevolentAI’s AI-drug discovery platform and experimentally validated by AstraZeneca. This is the first target to be selected from the extended… Read More
Cytokinetics has announced topline data from the Phase I study of cardiac myosin inhibitor CK-4021586 (CK-586), which met its primary and secondary objectives. The data support the advancement of CK-586 to a Phase II clinical trial in patients with heart failure with preserved ejection fraction (HFpEF) which… Read More
Corteria Pharmaceuticals has initiated a Phase I study to evaluate the company’s first-in-class corticotropin-releasing hormone receptor 2 (CRF2) agonist, COR-1167, for the treatment of Worsening Heart Failure (WHF). COR-1167 is a once-daily subcutaneous CRF2 agonist that has demonstrated substantial protective effects and functional improvement in the heart,… Read More
Gene therapy company Asklepios BioPharmaceutical (AskBio, a subsidiary of Bayer) has announced plans to initiate a Phase II trial of gene therapy AB-1002 for the treatment of congestive heart failure (CHF). GenePHIT (Gene PHosphatase Inhibition Therapy) will evaluate the safety and efficacy of a single intracoronary… Read More
Ethris and Heqet Therapeutics have revealed plans to collaborate on RNA-based therapeutics for heart attack and heart failure, using non coding RNAs (ncRNAs) in regenerating heart tissue. Under the terms of the agreement, Heqet Therapeutics will lead the development of the programme, while Ethris will provide… Read More
Asklepios BioPharmaceutical (AskBio), a gene therapy subsidiary of Bayer, has presented first-in-human data from a Phase I trial investigating AB-1002 (also known as NAN-101) for the treatment of patients with congestive heart failure (CHF). The data were shared at the American Heart Association Scientific Sessions, which… Read More
Researchers at the University of São Paulo (USP) in Brazil and Foresee Pharmaceuticals have tested a synthetic molecule which could increase heart function in patients with heart failure. Heart failure is a condition in which the heart cannot pump enough blood to meet the body’s needs… Read More
AstraZeneca’s Forxiga (dapagliflozin) has been approved in China to reduce the risk of cardiovascular death, hospitalisation for heart failure (HF), or urgent HF visits in adults with symptomatic chronic HF. The drug was previously approved in China but was limited to HF patients with reduced ejection… Read More
